Deuteroncology
Liege, BE · Founded 2022 · 101 employees on LinkedIn · 1 known investors
Find your way into Deuteroncology
356 people in our graph share verified history with the Deuteroncology team — schools, employers, funds. One of them is your warm intro.
Sandra Schwarzerunlockedknows Timothy Perera · together at University of London (overlapped)
×5knows the team · via University of London
×6knows the team · via Johnson & Johnson
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
Founders & leadership
Deuteroncology was founded in 2022 by Timothy Perera.
TP
Timothy PererainFounder & CEOTimothy Perera holds a Ph.D. in Cell Biology and has over 30 years of experience in oncology drug development. He previously served as Chief Scientific Officer and Founder of OCTIMET Oncology, a company he spun out from Janssen Pharmaceuticals where he had been Senior Director of Oncology Discovery, and now leads DeuterOncology as Founder and CEO.
Investors · 1
Frequently asked questions
- What does Deuteroncology do?
- DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
- Who founded Deuteroncology?
- Deuteroncology was founded by Timothy Perera in 2022.
- Who are Deuteroncology's investors?
- Deuteroncology's investors include Newton Biocapital.
- Where is Deuteroncology headquartered?
- Deuteroncology is headquartered in Liege, BE.